S&P 500

5.346,99

-0,11%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
2seventy bio Inc (TSVT)
2seventy bio Inc (TSVT) Notícias

TSVT

2seventy bio (TSVT)

2seventy bio Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:TSVT

1 2 3 4 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
05/06/2024	20:16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TSVT	2seventy bio Inc
23/05/2024	08:00	Business Wire	2seventy bio to Participate in Upcoming Investor Conferences	NASDAQ:TSVT	2seventy bio Inc
09/05/2024	17:03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:TSVT	2seventy bio Inc
08/05/2024	08:09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TSVT	2seventy bio Inc
08/05/2024	08:00	Business Wire	2seventy bio Reports First Quarter Financial Results and Recent Operational Progress	NASDAQ:TSVT	2seventy bio Inc
03/05/2024	08:00	Business Wire	2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024	NASDAQ:TSVT	2seventy bio Inc
05/04/2024	10:05	Business Wire	U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy	NASDAQ:TSVT	2seventy bio Inc
01/04/2024	08:30	Business Wire	2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron	NASDAQ:TSVT	2seventy bio Inc
20/03/2024	18:04	Business Wire	2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors	NASDAQ:TSVT	2seventy bio Inc
15/03/2024	19:27	Business Wire	FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy	NASDAQ:TSVT	2seventy bio Inc
07/03/2024	18:02	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:TSVT	2seventy bio Inc
05/03/2024	09:00	Business Wire	2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress	NASDAQ:TSVT	2seventy bio Inc
01/03/2024	09:00	Business Wire	2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences	NASDAQ:TSVT	2seventy bio Inc
05/02/2024	08:59	Business Wire	Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study	NASDAQ:TSVT	2seventy bio Inc
02/02/2024	18:54	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:TSVT	2seventy bio Inc
30/01/2024	11:25	AllPennyStocks.com	Biotech Shares Soar Premarket On Sale Of R&D Assets	NASDAQ:TSVT	2seventy bio Inc
30/01/2024	09:01	Business Wire	2seventy bio Announces New Strategic Path Forward	NASDAQ:TSVT	2seventy bio Inc
05/01/2024	18:31	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:TSVT	2seventy bio Inc
11/12/2023	21:30	Business Wire	Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3	NASDAQ:TSVT	2seventy bio Inc
11/12/2023	09:00	Business Wire	2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)	NASDAQ:TSVT	2seventy bio Inc
06/12/2023	16:00	Business Wire	2seventy bio Reiterates Commitment to Maximizing Shareholder Value	NASDAQ:TSVT	2seventy bio Inc
01/12/2023	08:49	Edgar (US Regulatory)	Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]	NASDAQ:TSVT	2seventy bio Inc
01/12/2023	08:40	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:TSVT	2seventy bio Inc
20/11/2023	16:31	Dow Jones News	Trending: Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA	NASDAQ:TSVT	2seventy bio Inc
20/11/2023	10:30	Dow Jones News	2seventy Bio Shares Fall Premarket on Abecma Expansion Delay	NASDAQ:TSVT	2seventy bio Inc
20/11/2023	09:56	Dow Jones News	FDA Advisory Panel to Meet on Earlier Use of Abecma From Bristol, 2seventy	NASDAQ:TSVT	2seventy bio Inc
20/11/2023	08:59	Business Wire	Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma	NASDAQ:TSVT	2seventy bio Inc
14/11/2023	09:00	Business Wire	2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress	NASDAQ:TSVT	2seventy bio Inc
10/11/2023	09:00	Business Wire	2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023	NASDAQ:TSVT	2seventy bio Inc
12/09/2023	08:00	Business Wire	2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway	NASDAQ:TSVT	2seventy bio Inc